Silo Pharma Files 8-K Report

TL;DR

Silo Pharma filed an 8-K on Jan 2, 2025, covering other events and financials.

AI Summary

On January 2, 2025, Silo Pharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Uppercut Brands, Inc., is incorporated in Nevada and has its principal executive offices in Sarasota, Florida.

Why It Matters

This filing provides official updates and financial information for Silo Pharma, Inc., which is important for investors and stakeholders to understand the company's current status and any material events.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K report, which typically contains updates on material events or financial statements, and does not inherently indicate significant new risks.

Key Numbers

• 001-41512 — SEC File Number (Identifies the company's filing with the SEC)
• 27-3046338 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant
• January 2, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• Sarasota, FL (location) — Address of principal executive offices
• Uppercut Brands, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar

Filing Documents

• ea0226314-8k_silopharma.htm (8-K) — 29KB
• ea022631401ex99-1_silopharma.htm (EX-99.1) — 24KB
• 0001213900-25-000191.txt ( ) — 229KB
• silo-20250102.xsd (EX-101.SCH) — 3KB
• silo-20250102_lab.xml (EX-101.LAB) — 33KB
• silo-20250102_pre.xml (EX-101.PRE) — 22KB
• ea0226314-8k_silopharma_htm.xml (XML) — 3KB

01 – Other Events

Item 8.01 – Other Events On January 2, 2025, Silo Pharma, Inc. (the "Company") issued a Letter to Shareholders highlighting the Company's progress and potential for its lead assets SPC-15 and SP-26 as treatments for mental health and chronic pain management, respectively A copy of the January 2025 Letter to Shareholders is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

Forward-looking Statements The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi)

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 January 2, 2025 Letter to Shareholders 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: January 2, 2025 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -2-

View Full Filing

View this 8-K filing on SEC EDGAR